Brief: Verrica Pharmaceuticals Announces Amendment to Company’s Collaboration and License Agreement with Torii Pharmaceutical Co. Ltd. to Fund Global Pivotal Phase 3 Clinical Trial to Study YCANTH® for the Treatment of Common Warts

Verrica Pharmaceuticals

15/05/2024 12:32

May 15 (Reuters) - Verrica Pharmaceuticals Inc  VRCA.O :
    * VERRICA PHARMACEUTICALS ANNOUNCES AMENDMENT TO COMPANY’S
COLLABORATION AND LICENSE AGREEMENT WITH TORII PHARMACEUTICAL
CO. LTD. TO FUND GLOBAL PIVOTAL PHASE 3 CLINICAL TRIAL TO STUDY
YCANTH® FOR THE TREATMENT OF COMMON WARTS
    * VERRICA PHARMACEUTICALS INC - GLOBAL PIVOTAL PHASE 3
CLINICAL
TRIAL WOULD BE CONDUCTED JOINTLY BY VERRICA AND TORII
PHARMACEUTICAL
    * VERRICA PHARMACEUTICALS INC - AMENDMENT SHOULD BENEFIT
BOTH
PARTIES FROM A COST AND TIME TO MARKET STANDPOINT
    * VERRICA PHARMACEUTICALS INC - FUNDING STRUCTURE IS
EXPECTED TO
HAVE A MINIMAL IMPACT ON VERRICA'S CASH POSITION
    * VERRICA PHARMACEUTICALS INC - GLOBAL PIVOTAL PHASE 3
CLINICAL
TRIAL EXPECTED TO BEGIN IN 1(ST) HALF OF 2025

Source text for Eikon:  ID:nGNX4F9Cj8 
Further company coverage:  VRCA.O 

 ((Reuters.Briefs@thomsonreuters.com;))